Table 3 Relationship between demographic, clinical characteristics and anticoagulant therapy in all patients and those with high risk of stroke
Variables | Classification | All patients n(%) | z/χ2 | p value | patients with high risk of stroke n(%) | z/χ2 | p value | ||
|---|---|---|---|---|---|---|---|---|---|
OAC | no OAC | OAC | no OAC | ||||||
Gender | Male | 114 (37.5) | 198 (63.5) | 1.795 | 0.180 α | 78 (35.8) | 140 (64.2) | 0.602 | 0.438 α |
Female | 88 (31.3) | 193 (68.7) | Â | Â | 69 (32.2) | 145 (67.8) | Â | Â | |
Payment | Self-paying | 32 (24.6) | 98 (75.4) | 6.618 | 0.010 α | 15 (21.1) | 56 (78.9) | 6.299 | 0.012 α |
Medical insurance | 170 (36.7) | 293 (63.3) | Â | Â | 132 (36.6) | 229 (63.4) | Â | Â | |
Age | < 60 | 31 (40.8) | 45 (59.2) | −3.017 | 0.003 β | 11 (73.3) | 4 (26.7) | 24.304 | 0.000 β |
60~69 | 57 (36.3) | 100 (63.7) | Â | Â | 35 (39.3) | 54 (60.7) | Â | Â | |
70~79 | 81 (39.5) | 124 (60.5) | Â | Â | 68 (39.1) | 106 (60.9) | Â | Â | |
≥80 | 33 (21.3) | 122 (78.7) |  |  | 33 (21.4) | 121 (78.6) |  |  | |
Education | Primary school or below | 103 (32.6) | 213 (67.4) | −0.290 | 0.771 β | 84 (32.7) | 173 (67.3) | 1.402 | 0.496 β |
Junior high school | 58 (40.0) | 87 (60.0) | Â | Â | 35 (39.3) | 54 (60.7) | Â | Â | |
Senior high school and above | 41 (31.1) | 91 (68.9) | Â | Â | 28 (32.6) | 58 (67.4) | Â | Â | |
AF type | Paroxysmal | 122 (32.0) | 259 (68.0) | −1.697 | 0.090 β | 82 (31.8) | 176 (68.2) | 2.298 | 0.317 β |
Persistent | 60 (34.9) | 112 (65.1) | Â | Â | 50 (35.7) | 90 (64.3) | Â | Â | |
Permanent | 20 (50.0) | 20 (50.0) | Â | Â | 16 (45.7) | 19 (54.3) | Â | Â | |
Duration | < 5 years | 129 (38.5) | 206 (61.5) | 6.768 | 0.009 α | 89 (38.2) | 144 (61.8) | 4.774 | 0.029 α |
≥5 years | 73 (28.3) | 185 (71.7) |  |  | 58 (29.1) | 141 (70.9) |  |  | |
Symptom of severity | Asymptomatic | 28 (45.9) | 33 (54.1) | −0.951 | 0.342 β | 20 (46.5) | 23 (53.5) | 4.143 | 0.246 β |
Mild | 108 (32.3) | 226 (67.7) | Â | Â | 77 (32.5) | 160 (67.5) | Â | Â | |
Moderate | 55 (32.5) | 114 (67.5) | Â | Â | 42 (31.6) | 91 (68.4) | Â | Â | |
Severe | 11 (37.9) | 18 (62.1) | Â | Â | 8 (42.1) | 11 (57.9) | Â | Â | |
Hypertension | Yes | 129 (35.9) | 230 (64.1) | 1.686 | 0.194 α | 115 (37.5) | 192 (62.5) | 5.565 | 0.018 α |
No | 72 (30.8) | 162 (69.2) | Â | Â | 32 (25.6) | 93 (74.4) | Â | Â | |
Vascular disease | Yes | 7 (25.9) | 20 (74.1) | 0.802 | 0.371 α | 18 (28.1) | 46 (71.9) | 1.166 | 0.280 α |
No | 194 (34.3) | 372 (65.7) | Â | Â | 129 (35.1) | 239 (64.9) | Â | Â | |
Diabetes mellitus | Yes | 46 (39.0) | 72 (61.0) | 1.702 | 0.192 α | 46 (40.4) | 68 (59.6) | 2.758 | 0.097 α |
No | 155 (32.6) | 320 (67.4) | Â | Â | 101 (31.8) | 217 (68.2) | Â | Â | |
Coronary heart disease | Yes | 41 (29.7) | 97 (70.3) | 1.406 | 0.236 α | 36 (31.6) | 78 (68.4) | 0.414 | 0.520 α |
No | 160 (35.2) | 295 (64.8) | Â | Â | 111 (34.9) | 207 (65.1) | Â | Â | |
Heart failure | Yes | 36 (37.9) | 59 (62.1) | 0.537 | 0.464 α | 30 (37.0) | 51 (63.0) | 0.402 | 0.526 α |
No | 155 (32.6) | 320 (67.4) | Â | Â | 117 (33.3) | 234 (66.7) | Â | Â | |
Hyperlipidemia | Yes | 8 (21.1) | 30 (78.9) | 2.989 | 0.084 α | 5 (20.0) | 20 (80.0) | 2.326 | 0.127 α |
No | 193 (34.8) | 362 (65.2) | Â | Â | 142 (34.9) | 265 (65.1) | Â | Â | |
Stroke | Yes | 19 (28.8) | 47 (71.2) | 0.865 | 0.352 α | 19 (29.2) | 46 (70.8) | 0.588 | 0.443 α |
No | 182 (34.5) | 345 (65.5) | Â | Â | 128 (34.9) | 239 (65.1) | Â | Â | |
Impaired renal/liver function | Yes | 13 (44.8) | 16 (55.2) | 1.626 | 0.202 α | 12 (44.4) | 15 (55.6) | 1.392 | 0.238 α |
No | 188 (33.3) | 376 (66.7) | Â | Â | 135 (33.3) | 270 (66.7) | Â | Â | |
HAS-BLED, score | < 3 | 180 (33.9) | 351 (66.1) | 0.062 | 0.803 α | 125 (33.8) | 245 (66.2) | 0.068 | 0.794 α |
≥3 | 22 (35.5) | 40 (64.5) |  |  | 22 (35.5) | 40 (64.5) |  |  | |
CHA2DS2-VASc, score | Male: 0~2; female: 0~1 | 56 (34.8) | 105 (65.2) | 0.062 | 0.804 α |  |  |  |  |
Male ≥3; female ≥2 | 155 (35.9) | 277 (64.1) |  |  |  |  |  |  | |